Understanding the Immune Response to Meningitis Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
MeningitisSepticemia
Interventions
BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Conjugate

2 x 0.5 mL dose

BIOLOGICAL

Meningococcal polysaccharide A, C, Y and W135 and Menveo

1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo

Trial Locations (1)

OX3 7LJ

University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

University of Oxford

OTHER